Teva: Our Biosimilars Strategy Has Been Fragmented, We Want To Be Global
Israeli Firm ‘Absolutely’ Believes Biosimilars Are Long-Term Growth Driver
Executive Summary
Months into the job, Teva CEO Richard Francis delivered the company’s promise for a new dedicated strategy to return to growth. Funded by a portion of capital reallocated from Teva’s generics business to focus on innovative brands, the new strategy will continue to promote biosimilars, Teva has outlined.
You may also be interested in...
Sandoz Follows US Denosumab Filing With European Acceptance
Sandoz has confirmed dual European filings for its denosumab biosimilar rival to Prolia and Xgeva, a few months after it submitted its candidate in the US.
Will Teva’s New Strategy Shift Towards Innovation?
Teva is just about to unveil a fresh strategy under new CEO Richard Francis, who has emphasized the firm’s “emerging innovative business” and talked up the company’s branded assets ahead of an investor day on 18 May where full details will be revealed.
Teva Expects To Carve Out Sizable Niche For Uzedy In Antipsychotic Market
Uzedy was recently approved by the US FDA as an extended-release subcutaneous formula of risperidone; it is poised to be a new prong in Teva’s branded portfolio.